Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Active, not recruiting
GlaxoSmithKline
Phase 1
2011-10-01
The purpose of this study is to determine the safety and toxicity of the combination of
pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated
dose (MTD) of this combination for phase II study.
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Active, not recruiting
National Comprehensive Cancer Network
Phase 1
2011-10-01
The purpose of this study is to determine the safety and toxicity of the combination of
pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated
dose (MTD) of this combination for phase II study.
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Active, not recruiting
Sidney Kimmel Comprehensive Cancer Center
Phase 1
2011-10-01
The purpose of this study is to determine the safety and toxicity of the combination of
pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated
dose (MTD) of this combination for phase II study.
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Completed
National Comprehensive Cancer Network
Phase 2
2013-02-01
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity
squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by
blocking an enzyme pathway needed for cell growth.
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Completed
Washington University School of Medicine
Phase 2
2013-02-01
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity
squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by
blocking an enzyme pathway needed for cell growth.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
